The totality of evidence from large-scale, randomized, controlled clinical trials and mechanistic studies in the laboratory has provided six crucial lessons about the emerging role of SGLT2 inhibitors to prevent the onset of heart failure in patients at high risk and slow the progression of heart failure in patients with established disease.
Your institute does not have access to this article
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Giugliano, D. et al. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc. Diabetol. 20, 236 (2021).
Packer, M. et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur. Heart J. 42, 671–680 (2021).
Usman, M. S. et al. Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure. ESC Heart Fail. 9, 885–893 (2022).
Packer, M. Does a target dose or a target heart rate matter to outcomes when prescribing β-blockers to patients with chronic heart failure? Circ. Cardiovasc. Qual. Outcomes 11, e004605 (2018).
Packer, M. & McMurray, J. J. V. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur. J. Heart Fail. 23, 882–894 (2021).
Shen, L. et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail. 9, 254–264 (2021).
Vaduganathan, M. et al. Estimating the benefits of combination medical therapy in heart failure with mildly reduced and preserved ejection fraction. Circulation https://doi.org/10.1161/CIRCULATIONAHA.121.058929 (2022).
Butler, J. et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur. Heart J. 43, 416–426 (2022).
Packer, M. et al. Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. Eur. J. Heart Fail. 23, 1798–1799 (2021).
Packer, M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance. Circulation 141, 2095–2105 (2020).
M.P. has received consulting fees from AbbVie, Actavis, Altimmune, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Lilly, Moderna, Novartis, Reata, Relypsa and Salamandra. M.P. has no current or planned financial relationships related to SGLT2 inhibitors or neprilysin inhibition.
About this article
Cite this article
Packer, M. Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure. Nat Rev Cardiol 19, 499–500 (2022). https://doi.org/10.1038/s41569-022-00736-3